Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH -17.40% Debt-to-Equity is 0.35 as of Dec. 2025, which is 20% below its 10-year median of 0.44. The stock has 4 warning signs investors should review. Among 812 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks worse than 57.39% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CTT Pharmaceutical Holdings's Debt-to-Equity or its related term are showing as below:
CTTH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.35 Med: 0.44 Max: 0.53
Current: 0.35
During the past 13 years, the highest Debt-to-Equity Ratio of CTT Pharmaceutical Holdings was 0.53. The lowest was 0.35. And the median was 0.44.
CTTH's Debt-to-Equity is ranked worse than 57.39% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs CTTH: 0.35
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CTT Pharmaceutical Holdings Debt-to-Equity Related Terms
CTT Pharmaceutical Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTTH vs BUDZ, SBFM, PRFX: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTT Pharmaceutical Holdings Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CTT Pharmaceutical Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTT Pharmaceutical Holdings (CTTH) has a Debt-to-Equity of 0.35 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CTT Pharmaceutical Holdings and its competitors. This is 20% below median its historical median of 0.44. Over the past decade, CTT Pharmaceutical Holdings' Debt-to-Equity has ranged from 0.35 to 0.53. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #466 out of 812 companies in the Drug Manufacturers industry, placing it in the top 57.4%.
Is CTT Pharmaceutical Holdings' Debt-to-Equity too high?
CTT Pharmaceutical Holdings' current Debt-to-Equity of 0.35 is 20% below median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 0.53. The Drug Manufacturers industry median Debt-to-Equity is 0.27. CTT Pharmaceutical Holdings' value of 0.35 is 29.6% above this industry median. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #466 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does CTT Pharmaceutical Holdings' Debt-to-Equity compare to BUDZ and SBFM?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #466 out of 812 companies for Debt-to-Equity. This places CTT Pharmaceutical Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.27. CTT Pharmaceutical Holdings' value of 0.35 is 29.6% above this benchmark. Historically, CTT Pharmaceutical Holdings' own Debt-to-Equity has ranged from 0.35 to 0.53 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 0.27, CTT Pharmaceutical Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CTT Pharmaceutical Holdings's current Debt-to-Equity of 0.35 is 29.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CTT Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current Debt-to-Equity is 0.35, which is 20% below median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current Debt-to-Equity of 0.35. The current Debt-to-Equity is 0.35, which is 20% below median its 10-year median of 0.44 and 29.6% above the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current Debt-to-Equity is 0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
